Goodwin Advises Ascidian Therapeutics on Entering Strategic Agreement With Exegenesis Bio

The Life Sciences team advised Ascidian Therapeutics on its strategic agreement with Exegenesis Bio, a global gene therapy company with proprietary AI-enabled optimized adeno-associated virus capsid discovery capabilities. The strategic agreement combines Ascidian’s RNA exon editing technology with Exegenesis Bio’s capsid engineering and discovery workflows. The partnership enables novel delivery approaches tailored to the specific clinical needs of individual programs. Collaborative scientific work underway will accelerate in vivo data generation and progression toward clinical development for a suite of RNA exon editors targeting devastating diseases.

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With partnered and wholly owned programs in retinal, renal, neurological, neuromuscular, and genetically defined diseases, Ascidian’s approach has the potential to treat patients with one dose of an RNA exon editor, opening new therapeutic possibilities for patients and their families who are seeking breakthroughs.

The Goodwin team was led by Erini Svokos and Evan De Ycaza, with invaluable assistance from Alex Valenti and Amber Bolden.

For more information on the deal, please read the press release.